SCYNEXIS, Inc. announced on October 3, 2024, that it would present preclinical efficacy and pharmacokinetic data for its second-generation fungerp candidate, SCY-247, at IDWeek 2024. The conference is scheduled to take place in Los Angeles, CA, from October 16-19, 2024.
SCY-247 is a pre-IND development stage antifungal compound designed to address antimicrobial resistance in systemic fungal diseases. It has demonstrated broad-spectrum antifungal activity in vitro and in vivo, including against multidrug-resistant fungal pathogens.
The company anticipates that the U.S. Food and Drug Administration (FDA) may grant SCY-247 Qualified Infectious Disease Product (QIDP) and Fast Track designations for both its IV and oral formulations. This presentation underscores SCYNEXIS's commitment to advancing its novel fungerp platform.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.